Rapid detection of pathological mutations and deletions of the haemoglobin beta gene (HBB) by High Resolution Melting (HRM) analysis and Gene Ratio Analysis Copy Enumeration PCR (GRACE-PCR) by Turner, Andrew et al.
TECHNICAL ADVANCE Open Access
Rapid detection of pathological mutations
and deletions of the haemoglobin beta
gene (HBB) by High Resolution Melting
(HRM) analysis and Gene Ratio Analysis
Copy Enumeration PCR (GRACE-PCR)
Andrew Turner1*, Jurgen Sasse1 and Aniko Varadi2
Abstract
Objectives: Inherited disorders of haemoglobin are the world’s most common genetic diseases, resulting in significant
morbidity and mortality. The large number of mutations associated with the haemoglobin beta gene (HBB) makes
gene scanning by High Resolution Melting (HRM) PCR an attractive diagnostic approach. However, existing HRM-PCR
assays are not able to detect all common point mutations and have only a very limited ability to detect larger gene
rearrangements. The aim of the current study was to develop a HBB assay, which can be used as a screening test in
highly heterogeneous populations, for detection of both point mutations and larger gene rearrangements.
Methods: The assay is based on a combination of conventional HRM-PCR and a novel Gene Ratio Analysis Copy
Enumeration (GRACE) PCR method. HRM-PCR was extensively optimised, which included the use of an unlabelled
probe and incorporation of universal bases into primers to prevent interference from common non-pathological
polymorphisms. GRACE-PCR was employed to determine HBB gene copy numbers relative to a reference gene using
melt curve analysis to detect rearrangements in the HBB gene. The performance of the assay was evaluated by
analysing 410 samples.
Results: A total of 44 distinct pathological genotypes were detected. In comparison with reference methods, the assay
has a sensitivity of 100 % and a specificity of 98 %.
Conclusion: We have developed an assay that detects both point mutations and larger rearrangements of the HBB
gene. This assay is quick, sensitive, specific and cost effective making it suitable as an initial screening test that can be
used for highly heterogeneous cohorts.
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Background
According to the World Health Organization (WHO),
inherited disorders of haemoglobin are the most com-
mon monogenic disorders in the world. The WHO
estimates that 300,000 to 400,000 severely affected in-
fants are born each year and that greater than 95 % of
these severe cases arise from genetic abnormalities of
the β-globin gene (HBB) [1]. Globally, these conditions
result in significant childhood morbidity and mortality.
The HBB gene is 1606 base pairs long, contains three
exons and is located on the short arm of chromosome
11 towards the 3’ end of a 70 kb region known as the β-
globin locus. The HBB gene codes for β-globin, a protein
that is an essential component of normal adult haemo-
globin [2]. To date, 868 mutations of the HBB gene have
been described that have either a qualitative or quantita-
tive effect on β-globin synthesis. These include point
mutations, small insertions / deletions (indels) and larger
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gene rearrangements [3]. Qualitative defects are normally
the result of point mutations and lead to the formation of
abnormal β-globin chains, which in turn give rise to
variant haemoglobins. Quantitative defects of the HBB
gene either reduce, or totally stop, the synthesis of β-
globin resulting in β-thalassaemia. Unlike α-thalassaemia,
which is mostly caused by large deletions, the majority of
β-thalassaemia alleles are the result of point mutations or
small indels. However, in recent years several novel dele-
tions of the HBB gene have been identified and it has
become apparent that deletional forms of β-thalassaemia
are more prevalent than was previously thought. Indeed, it
has been suggested that large deletions may account for as
much as 10 % of β-thalassaemia mutations [4].
Premarital screening programs specifically targeting β-
thalassaemia were introduced in Greece [5] and Cyprus
[6, 7] in the 1970s. These programs significantly reduced
the number of children being born with β-thalassaemia,
and as a result similar programs were subsequently in-
troduced in a number of countries where the disease is
prevalent [8]. The success of such premarital screening
programs is dependent on reliable laboratory tests for
the detection of carriers.
In general, carriers for the common variant haemoglo-
bins are readily detected by routine biochemical tech-
niques, such as cation exchange High Performance
Liquid Chromatography (HPLC) or capillary elec-
trophoresis (CE). However, reliable detection of β-
thalassaemia carriers can be more challenging [9].
Haemoglobin A2 (Hb A2) quantification is widely used
for screening, since Hb A2 is easily quantified by
HPLC or CE and shows a modest increase in the ma-
jority of individuals with β-thalassaemia trait [10].
However, some β-thalassaemia mutations result in
only minimal increases in Hb A2 levels and are easily
missed during screening [11]. Interpretation of β-
thalassaemia screening results can be further compli-
cated by external factors that may influence the Hb A2
level. For example, Hb A2 is lowered by both iron defi-
ciency [12] and α-thalassaemia [13], but is elevated by
mutations in the Krüppel-like Factor 1 (KLF1) gene
[14]. In addition, co-inheritance a of β-thalassaemia
trait with a δ-globin gene (HBD) mutation can lead to
Hb A2 levels that are normal or even reduced [11].
Consequently, although Hb A2 quantification remains
a useful screening tool, confirmation by molecular
analysis is frequently required [15].
A variety of PCR techniques, such as Amplification
Refractory Mutation System (ARMS) PCR, Allele Specific
Oligonucleotide (ASO) PCR and real time PCR have been
used to detect β-thalassaemia resulting from point muta-
tions or indels [16–18], while Gap-PCR is normally used
to detect larger gene rearrangements [4]. These assays are
designed to detect either a single specific mutation or a
small set of mutations. This approach works well in popu-
lations where a limited number of β-thalassaemia muta-
tions are prevalent, but is less useful when testing highly
heterogeneous populations where the range of muta-
tions is less predictable. In such situations gene scan-
ning methods may be useful and assays using various
technologies including Denaturing HPLC (DHPLC),
Single Strand Conformational Polymorphism (SSCP)
and Denaturing Gradient Gel Electrophoresis (DGGE)
have been described [19]. These assays offer an alter-
native means of detecting point mutations or indels of
the HBB gene, but are not appropriate for the detec-
tion of larger deletions and have the disadvantage of
being open tube techniques that require significant
post amplification processing.
An alternative gene scanning technology called High
Resolution Melting PCR (HRM-PCR) offers potential
advantages over the other techniques since it does not
require complicated post amplification processing by
chromatography or polyacrylamide gel electrophoresis
[20]. HRM-PCR is a closed tube technique that allows
both amplification and detection to be performed on the
same instrument without requiring further hands-on
time after the initial PCR setup [20]. Thus, HRM-PCR is
well suited to clinical applications, since it permits a
simple and efficient workflow, with minimal risk of
amplicon contamination. In addition to being quicker
and easier to perform, HRM-PCR has specificity and
sensitivity equal to, or better than, other gene scanning
technologies such as DHPLC [21, 22]. These advantages
have resulted in the application of HRM-PCR in a wide
range of clinical settings [23–28].
HRM-PCR assays for scanning the HBB gene mutations
have been described, targeting the most common muta-
tions found in Chinese [29] and South East Asian [30, 31]
populations. These assays are well suited for screening the
specific cohorts targeted. However, the approaches used to
overcome interference from high frequency single nucleo-
tide polymorphisms (SNPs) made these assays insensitive
to some important pathological mutations that are com-
mon in other populations including Hb S and Hb C. Add-
itionally, with the exception of the 3.4 kb deletion, these
assays cannot detect larger gene rearrangements [31].
We have recently developed a Gene Ratio Copy
Enumeration PCR (GRACE-PCR) to determine copy
numbers for the α-globin genes [32] and we describe a
similar approach for the detection of deletions of the
HBB gene. We also developed a HRM-PCR method that
was optimized with the use of an unlabelled probe and
primers containing universal bases to address the issue
of SNP interference. The combined use of GRACE-PCR
and HRM-PCR allowed for the detection of point muta-
tions, indels and larger deletions of the HBB gene, thus
resulting in an assay that is universally applicable.
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Materials and methods
Samples and cohort selection
This study was conducted using anonymous, archived
material from blood specimens submitted to the Sheikh
Khalifa Medical City (SKMC) laboratory, Abu Dhabi,
United Arab Emirates (UAE) for thalassaemia/
haemoglobinopathy screening. Ethical clearance was ob-
tained from the SKMC Institutional Research and Ethics
Committee to use this material for the current study.
Since the study used anonymous archived material it was
not possible to identify the subjects, therefore specific in-
formed consent was not possible. The material used con-
tained no patient identifiers, but the results of the
haemoglobin analysis by HPLC had been assigned prior to
the anonymization of samples. A total of 410 samples were
used in the study, these included 305 with elevated Hb A2
(Hb A2 > 3.5 %), 27 with low or normal Hb A2, 76 with
abnormal haemoglobins and two samples known to be
positive for the 619 base pair deletion (NM_000518.4:
c.316-149_*342delinsAAGTAGA) [33]. The initial assess-
ment of the assay was conducted using 342 of these samples
and an additional 68 were used for a blinded validation.
DNA extraction
Genomic DNA was extracted from whole blood using
the QIAamp DNA Blood Mini kit (Qiagen, Germany)
in accordance with the manufacturer’s instructions. The
concentration of the extracted DNA was measured
using a NanoDrop 2000 spectrophotometer (Thermo
Scientific, USA) and adjusted to 10 ng/μl with 10 mM
Tris, 0.5 mM EDTA (pH 9.0).
Primer design and synthesis
Analysis of the HbVar online database (http://globin.bx.p-
su.edu/hbvar/menu.html) was performed to identify the
regions of the HBB gene of potential clinical relevance
and to identify the breakpoints for known gene deletions.
The final version of the assay used a total of 13 PCR reac-
tions, 11 HRM-PCRs to scan for point mutations and
indels of the HBB gene and two GRACE-PCRs for the de-
tection of larger gene rearrangements (Table 1 and Fig. 1).
The previously described primer set H7 [29] was in-
cluded to test for the HBB:c.316-197C > T mutation found
in intervening sequence two (IVS2). The reverse primers
in primer sets H6 and H7 incorporated the universal base
inosine to eliminate the risk of potential interference from
common non-pathological SNPs (Table 1). In addition, an
unlabelled probe was designed to overlap the region of the
first exon containing the HBB:c.19G >A and HBB:c.20A >T
mutations (Fig. 1 and Table 1). This probe was designed
to have a melting temperature approximately 8 °C lower
than the corresponding amplicon and was synthesized
with a phosphate block at the 3’ prime end to prevent it
from acting as a primer.
Primer sets G1 and G2 were used to amplify targets in
the HBB gene promoter and third exon, respectively.
These primers were designed to be used in GRACE-PCR
with primer set G3, which amplifies a target in the
CLCN7 reference gene [34].
All primers were checked for specificity using the NCBI
Primer BLAST program (http://www.ncbi.nlm.nih.gov/
tools/primer-blast). HPLC purified primers and probes
were commercially synthesized (Metabion, Germany).
PCR reaction conditions
For scanning the HBB gene by HRM with primers sets H1
to H11 each 10 μl HRM-PCR reaction included 5 μL of
LightCycler® 480 High Resolution Melting Master (Roche
Diagnostics, Germany), 3.75 mM MgCl2, 25 ng of genomic
DNA and 0.2 μM of each primer. When the unlabelled
probe was included, it was used at a concentration of
0.2 μM and the forward primer concentration was reduced
to 0.02 μM. PCR was performed using a Rotor-Gene Q-
5plex HRM thermocycler (Qiagen). This system can ac-
commodate up to 72 PCR reactions per run. After a
10 min hold at 95 °C, 45 cycles of PCR were performed as
follows: 15 s at 95 °C, 15 s at the temperature given in
Table 1, 15 s at 72 °C. Cycling was followed by a 2 min
hold at 72 °C, a 1 min hold at 95 °C and then a 1 min hold
at 40 °C. Amplicon melting was performed at a rate of
0.1 °C/s over the temperature ranges indicated in Table 1.
For the detection of deletions in the promoter of the
HBB gene promoter, each 12.5 μL GRACE-PCR reaction
included 0.25 units of Kappa HiFi HotStart polymerase
(Kappa Biosystems, USA), 0.25 units of Platinum Taq
polymerase (Invitrogen, USA), 1x Kappa GC buffer (Kappa
Biosystems), 0.3 mM of each dNTP (Kappa Biosystems),
0.25 μL Resolite dye (Roche Diagnostics), 25 ng of genomic
DNA, 0.16 μM of each G1 primer and 0.1 μM of each G3
primer (Table 1). After a 2 min hold at 98 °C, 26 cycles of
PCR were performed as follows: 15 s at 95 °C, 15 s at 55 °C,
15 s at 72 °C. Melting was performed from 75 to 90 °C at a
rate of 0.2 °C/s.
For the detection of deletions in the third exon of the
HBB gene, each 10 μL GRACE-PCR reaction included
5 μL of LightCycler® 480 High Resolution Melting Master
(Roche Diagnostics), 3.0 mM MgCl2, 25 ng of genomic
DNA, 0.2 μM of each G2 primer and 0.08 μM of each G3
primer (Table 1). After a 10 min hold at 95 °C, 26 cycles
of PCR were performed as follows: 15 s at 95 °C, 15 s at
55 °C, 15 s at 72 °C. Melting was performed from 80 to
90 °C at a rate of 0.2 °C/s.
Acquisition and analysis of data
Data acquisition and analysis were performed using the
Rotor-Gene Q series software version 1.7 (Qiagen). For
gene scanning by HRM, the raw melting curves were
normalized and then converted to difference plots
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(Figs. 2 and 3). For the determination of gene copy
number by GRACE-PCR, the melt curves were normal-
ized before the melting of the CLCN7 control gene and
after the HBB gene (Fig. 4). This resulted in a plot which
allowed the CLCN7:HBB ratio to be determined by
simple visual examination (Fig. 4b). Since the copy num-
ber of the CLCN7 gene is assumed to be two, the copy
number of the HBB gene is easily derived.
Confirmation of deletions in the HBB gene
The Filipino β-thalassaemia deletion (NG_000007.3:g.
66258_184734del118477) [3, 35] was confirmed by Gap-
PCR using previously described primers [36]. Each
12.5 μL PCR reaction included 0.25 units of Platinum
Taq, 1x PCR buffer (Invitrogen), 0.3 mM of each dNTP,
2.0 mM MgCl2, 0.1 μM of each primer and 25 ng of
genomic DNA (Table 2). After an initial 4 min hold at
94 °C, 38 cycles of PCR was performed as follows: 30 s
at 94 °C, 30 s at 60 °C, 60 s at 72 °C. PCR products were
evaluated by electrophoresis using 1 % agarose gels, with
detection of a 920 bp product indicating the presence of
the deletion.
The presence of the 619 bp deletion of the HBB gene
was confirmed using the commercial β-Globin StripAssay
(ViennaLab Diagnostics, Austria) in accordance with the
manufacturer’s instructions.
Sequencing of the HBB gene
Amplicons for sequencing were obtained using the
primers and reaction conditions given in Table 2. The
Table 1 Primers for the HRM-PCR/GRACE-PCR assay of the HBB gene










H1 Forward 5’-GGCTGTCATCACTTAGACCTCA-3’ 5,227,065 to 5,227,196
on NC_000011.10
132 HBB Promoter 59 80–90
Reverse 5’-CAAATGTAAGCAATAGATGGCTC-3’
H2 Forward 5’-ATTTGCTTCTGACACAACTG-3’ 5,226,952 to 5,227,069
on NC_000011.10




H3 Forward 5’-TGCCGTTACTGCCCTGT-3’ 5,226,886 to 5,226,992
on NC_000011.10
107 HBB Exon 1 59 75–85
Reverse 5’-TTCTATTGGTCTCCTTAAACCTGT-3’
H4 Forward 5’-CACTGACTCTCTCTGCCTA-3’ 5,226,726 to 5,226,841
on NC_000011.10
116 HBB Exon 2 59 80–90
Reverse 5’-TAACAGCATCAGGAGTGGACA-3’
H5 Forward 5’-GTCTACCCTTGGACCCAG-3’ 5,226,674 to 5,226,789
on NC_000011.10
116 HBB Exon 2 59 80–90
Reverse 5’-CTAAAGGCACCGAGCACT-3’
H6 Forward 5’-GCTCATGGCAAGAAAGTGCTC-3’ 5,226,549 to 5,226,705
on NC_000011.10
157 HBB Exon 2 59 80-90
Reverseb 5’-GAAAACATCAAGIGTCCCA-3’
H7 Forward 5’-TGCCTCTTTGCACCATTCTA-3’ 5,225,893 to 5,225,974
0n NC_000011.10
82 HBB IVS2 55 70–80
Reverseb 5’-GAAATATTTATATGCAGAIATATTGCTA-3’
H8 Forward 5’-CTAATAGCAGCTACAATCCAG-3’ 5,225,702 to 5,225,852
on NC_000011.10
152 HBB IVS2 56 80–90
Reverse 5’-CACAGACCAGCACGTT-3’
H9 Forward 5’-TTGCTAATCATGTTCATACCTC-3’ 5,225,632 to 5,225,765
on NC_000011.10
134 HBB Exon 3 59 80–90
Reverse 5’-CCAGCCACCACTTTCTGAT-3’
H10/G2 Forward 5’-GAATTCACCCCACCAGTGC-3’ 5,225,559 to 5,225,678
on NC_000011.10
120 HBB Exon 3 55 80–90
Reverse 5’-AGGAACCTTTAATAGAAATTGGAC-3’
H11 Forward 5’-CCCACAAGTATCACTAAGCTC-3’ 5,225,423 to 5,225,614
on NC_000011.10
192 HBB Exon 3 55 78–88
Reverse 5’-CCCTTTTTAGTAAAATATTCAGA-3’
G1 Forward 5’-TGAAGTCCAACTCCTAAGCC-3’ 5,227,086 to 5,227,243
on NC_000011.10
158 HBB Promoter 55 75–90
Reverse 5’-TCTGCCCTGACTTTTATGCC-3’
G3 Forward 5’-CACCCGGCCTCATGGAT-3’ 1,462,101 to 1,462,255
on NC_000016.10




Primer sets H1 to H11 were used to scan the HBB gene for mutations by HRM. Primers sets G1 and G2 were used to detect deletions of the HBB gene promoter
and third exon by GRACE-PCR. Primer set G3 is the internal control for the GRACE-PCR reactions
aThe probe used in conjunction with primer set H2 is an unlabelled oligonucleotide that has a phosphate block at the 3’ end
bThe reverse primers of primer sets H6 and H7 contain the universal base inosine, indicated with an I in the primer sequence
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PCR products were diluted 1:150 with distilled water prior
to cycle sequencing. Cycle sequencing was performed with
the BigDye Terminator v3.1 Cycle Sequencing kit (Applied
Biosystems, USA) in accordance with the manufacturer’s
instructions using M13 primers. Cycle sequencing prod-
ucts were cleaned by an ethanol and ethylenediaminetetra-
acetic acid (EDTA) precipitation and sequenced on a 3130
Genetic Analyser (Applied Biosystems).
Results
Amplicon and primer design
When a common non-pathological SNP was present in a
region that was optimal for primer placement, we
substituted the nucleotide at the SNP position with the
universal base inosine. Incorporating inosine into the
primer allows equal amplification of both the wild-type
and variant alleles [37]. This proved to be a good strategy
for obtaining clear HRM-PCR profiles without interfer-
ence by the non-pathological SNP. The SNPs concerned
were rs10768683 (HBB:c.315 + 16G > C) under the reverse
H6 primer and rs1609812 (HBB:c.316-185C > T) under
the reverse H7 primer (Table 1). An example showing the
detection of the HBB:c.315 + 1G >A mutant and wild type
alleles where inosine in the primer was used to mask the
non-pathological SNP rs10768683 is shown in Fig. 2, plots
1A and 1B, and Table 3 (genotype 37).
The CLCN7 gene was selected as a reference gene for
GRACE-PCR [32]. As previously described, the CLCN7
gene is well suited as a reference gene since it has no
pseudo genes and defects in the gene result in an obvi-
ous phenotype [34, 38]. The G3 primer set was designed
to target the CLCN7 gene and generate a product with a
melting temperature approximately 8 °C lower that the
products of the G1 and G2 primer sets. This resulted in
GRACE-PCR melting curves with two distinct steps cor-
responding to the melting of the reference gene product
and the HBB product (Fig. 4). The drop in fluorescence
as each product melts is proportional to the amount of
the product present. Limiting the number of cycles to 26
ensured that the amount of products remained propor-
tional to the gene copy numbers. Thus, normalized melt
curve data allowed the number of gene copies to be
determined by simple visual analysis (Fig. 4b).
Initial assessment of the assay
The assay was initially assessed using 342 samples for
which the HBB gene had been previously sequenced and
included two samples positive for the 619 bp deletion.
For 26 of these samples the assay did not yield the ex-
pected result, with 23 due to interference from the com-
mon synonymous SNP HBB:c.9C > T, two due to
deletions and one was an abnormal melt curve obtained
with primer set H1.
The initial version of the assay was not able to distinguish
heterozygous Hb C (Table 3; Genotype 7, HBB:c.19G >A;
n = 5) from the heterozygous form of the common syn-
onymous SNP HBB:c.9C > T (Fig. 3a and b). Likewise,
homozygous Hb S (Table 3; Genotype 10, HBB:c.20A >T;
n = 18) could not be distinguished reliably from the homo-
zygous form of the HBB:c.9C > T SNP. This issue was re-
solved by the use of the unlabelled probe [37, 39] designed
to cover the HBB:c.19G >A and HBB:c.20A >T mutations,
but not the nearby HBB:c.9C >T SNP (Fig. 1 and Table 1).
This approach resulted in clear separation of the patho-
logical mutations in the probe melt region (Fig. 3c). Repeat-
ing the HRM-PCR analysis in the presence of the
unlabelled probe for the 23 samples in which a mutation
was initially missed, yielded results consistent with sequen-
cing (Table 3; columns Sequencing versus Sample set 1).
GRACE-PCR correctly detected the two samples
known to be positive for the 619 bp deletion as having
deletions of the third exon of the HBB gene (Table 3,
genotypes 42 and 43). GRACE-PCR also indicated that
two additional samples had large deletions of the HBB
gene involving both the promoter and the third exon.
Both of these unexpected cases were subsequently con-
firmed by Gap-PCR to be positive for the Filipino β-
thalassaemia deletion (Table 3, genotype 44).
Fig. 1 Schematic representation the HBB gene showing amplicons and probe positions. A total of 11 primer pairs were used to scan the HBB
gene by HRM-PCR (H1 to H11). In addition two primer pairs where used to test for deletions by GRACE-PCR (G1 and G2). The unlabelled probe
(indicated by P) was used in conjunction with primer set H2. Primer sets H6 and H7 incorporated the universal base inosine in place of common
non-pathological SNPs (See sequence information in Table 1)
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After modifying the assay to include the probe and
confirming the presence of the deletions, only one of the
342 samples in the initial assessment failed to give the
expected result. This sample produced an abnormal
melting curve with the H1 primer set the first time it
was tested. On retesting the sample was found to be wild
type, this sample is listed as a false positive in Table 3.
Validation of the assay
An additional 68 samples without prior sequence infor-
mation were analysed by the assay. Sixty three samples
had HRM melting curves that indicated the presence of
sequence variations, other than the common HBB:c.9C >
T SNP, and for one sample GRACE-PCR indicated a
gene deletion. For the remaining four samples there was
no evidence of a sequence change. It was noted that the
HRM-PCR difference plots were highly reproducible
between runs and between samples (Fig. 2; panels a
versus b). This raised the possibility that HRM-PCR
could be used not only to detect sequence variations but
also reveal the actual nucleotide change. For 53 of the
63 samples in which a sequence variation was detected,
it was possible to assign a provisional genotype based
only on the HRM-PCR data. Subsequent sequencing of
the HBB gene confirmed that the four samples without
variation by HRM-PCR had not contained any sequence
changes, and that the 63 samples identified with varia-
tions all carried pathological mutations. The sample,
Fig. 2 Representative HRM-PCR difference plots. Difference plots show wild type samples and the various mutants: 1a&b – genotype 37;
2a&b – genotype 28; 3a&b – genotype 33; 4a&b – genotype 2; 5a&b – genotypes 24 and 18 (see Table 3). Plots 1a&b were generated using primer pair
6 containing the universal base inosine (Table 1). Panels a and b show different runs with different samples
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which tested positive by GRACE-PCR, was confirmed by
Gap-PCR to be another example of the Filipino β-
thalassaemia deletion. Furthermore, all 53 of the
provisional genotypes assigned by analysis of the HRM-
PCR data were proved to be correct. The 10 samples, for
which no provisional genotype could be assigned, were
found to have genotypes that were either absent, or only
present in a very few cases in the initial 342 samples
(Table 3; columns Sample set 2 versus Sample set 1).
A combination of sequencing, Gap-PCR and the
commercial β-globin StripAssay showed that 361 of the
410 samples included in the study contained one or more
mutations in the HBB gene. The assay was able to detect
all 361 abnormal samples and generated just one false
positive result (Table 3; columns Sequencing versus
Sample sets 1&2). This equates to a sensitivity of 100.0 %
(95 % confidence interval 98.7 - 100.0 %) and a specificity
of 98.0 % (95 % confidence interval 87.8 – 99.9 %). In
total, the 361 positive samples in the study accounted for
44 distinct pathological genotypes (Table 3).
Discussion
Quantification of Hb A2 is routinely used for the detec-
tion of β-thalassaemia carriers. The normal range for Hb
A2 is 2.0–3.3 % with levels above 3.5 % being considered
indicative of β-thalassaemia trait [11]. The current study
included 22 samples with Hb A2 levels greater than
3.5 %, which did not have detectable mutations or dele-
tions of the HBB gene. This is in line with previous
observations that false positive results can be a signifi-
cant problem when screening for β-thalassaemia carriers
based on Hb A2 levels [40]. Indeed, elevated Hb A2 in
the absence of β-thalassaemia has recently been linked
to mutations in the KLF1 gene [14], suggesting that
molecular confirmation may be required. In our labora-
tory, HBB gene mutations are routinely detected with a
commercial reverse hybridization assay (ViennaLab
Diagnostics). This commercial kit was designed to detect
the 22 most prevalent mutations found in Indian and
Middle Eastern populations. The current study identified
63 samples (15.4 %) with mutations not targeted by this
kit (Table 3). This further illustrates the limitations of
conventional PCR techniques when screening for β-
thalassaemia trait in highly heterogeneous populations,
and highlights the advantages of using a more universal
assay, such as the one described here.
The first application of HRM-PCR to the HBB gene
was described by Wittwer et al. [41]. This was a small-
Fig. 3 Representative unlabelled probe HRM-PCR difference plots. Addition of the unlabeled probe allows differentiation of the pathological
HBB:c.19G > A heterozygotes from common non-pathological HBB:c.9C > T heterozygotes; and of HBB:c.20A > T homozygotes from HBB:c.9C > T
homozygotes. The unlabeled probe produced distinct probe and amplicon melt regions (a). Certain pathological variants cannot be distinguished from
the HBB:c.9C > T SNP in the amplicon melt region (b), but are clearly separated in the probe melt region (c)
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scale study designed to detect the mutations responsible
for the abnormal haemoglobins Hb S and Hb C [41].
Despite the fact that they amplified approximately the
same section of the gene covered by the H2 primer set
in the current study, the authors did not report any
problems with the HBB:c.9C > T SNP. This is presum-
ably due to the relatively small number of samples tested
(n = 12). In contrast, in the current study the HBB:c.9C >T
SNP was encountered frequently and it was not possible
to resolve all genotypes without the addition of the
unlabelled probe.
Three previous studies have described HRM-PCR
assays to scan the HBB gene in different populations.
Shih et al. [30], Saetung et al. [31] and Lin et al. [29]
used the technique to detect the most prevalent muta-
tions in Taiwanese, Thai and Chinese populations
respectively [29–31]. These assays scanned selected areas
of the HBB gene and the assay described by Saetung et al.
also included a tube for the detection of the 3.4 kb
deletion. Both Shih et al. [30] and Lin et al. [29] reported
problems with the HBB:c.9C > T SNP, which were resolved
by placing the primer over the SNP. A possible concern
with this approach is that it might result in allele dropout,
particularly if a SNP is located close to the 3’ end of a pri-
mer. The primers described by Shih et al. [30] put the SNP
close to the 3’ end, while the primer used by Lin et al. [29]
place the SNP in the middle of the primer where it is
less likely to have a significant effect. However, the
HBB:c.19G > A and HBB:c.20A > T mutations are lo-
cated at the 3’ end of the primer used by Lin et al.
[29], which would probably affect the amplification of
these common pathologically significant alleles. Since
these mutations are rare in China [42] and were not
included in the specific mutations being targeted this
would not have been a significant concern when
screening that population. However, these mutations
are very common throughout Africa and the Middle
East [43], thus the assay described by Lin et al. [29]
is not well suited for screening in these regions. In
contrast to overlaying the HBB:c.9C > T SNP with a
primer, the approach described here of using the un-
labelled probe, allowed detection of all the mutations
we encountered in this area of the HBB gene.
Saetung et al. [31] avoided complications from the
HBB:c9.C > T SNP by simply not scanning this region of
the HBB gene. This approach limits the usefulness of
their assay in populations where mutations in this area
of the gene are common.
Other high frequency SNPs also complicated HRM ana-
lysis of the HBB gene. These were HBB:c.315 + 16G > C
(rs10768683) and HBB:c.316-185C > T (rs1609812). We
addressed this issue by substituting the respective SNP
with inosine in each primer designed to cover these bases.
This approach, as previously demonstrated for the BRCA
genes [37], eliminated the detection of this high frequency
SNP and provided clean HRM profiles (Fig. 2; 1a and 1b).
Until recently, deletions of the HBB gene were consid-
ered to be rare with only the 619 base deletion being
common, accounting for around 20 % of β-thalassaemia
alleles in some parts of India and Pakistan [2]. However,
it has now become apparent that HBB gene deletions
are more frequent than was previously believed. The
3.4 kb deletion has a prevalence of up to 4 % in some
parts of Thailand [44] and the Filipino β-thalassaemia
deletion has been described as being a common cause of
Fig. 4 GRACE-PCR to determine copy numbers of the HBB gene.
Limited cycle GRACE-PCR was used to amplify targets from the
CLCN7 reference gene [34] and the HBB gene. The raw melt curves
(a) are difficult to interpret, but after normalization (b) the ratio of
CLCN7:HBB gene copy numbers is easily visualized
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β-thalassaemia in Filipinos [36, 45]. Indeed, it has been
suggested that deletions involving the β-globin gene
cluster account for as many as 10 % of all β-thalassaemia
mutations [4].
Conventional HRM-PCR works well for the detection
of point mutations and small indels, but is not a useful
technique for the detection of larger gene rearrange-
ments. Melting curve assays have been described to
detect the 3.4 kb deletion of the HBB gene [31, 44].
However, for other deletions Gap-PCR is still commonly
used. Although Gap-PCR is a simple and robust tech-
nique, it is not ideal for high volume screening, since the
use of agarose gel electrophoresis for detection makes it
a time consuming open tube technique. An important
limitation of both Gap-PCR and the existing melt curve
assays is that they can only be used to detect specific
deletions with well-defined breakpoints and conse-
quently are not suitable for the detection of novel or
rare deletions. In contrast, the GRACE-PCRs included
in the current study determine the copy number ratio
between the HBB gene and the reference gene. Thus
GRACE-PCR can be used to detect large rearrangements
of the HBB gene without prior knowledge of the break-
points. In order to maximise the number of deletions
that could be detected our assay used two GRACE-PCR
reactions, one targeting the promoter and the other
targeting the third exon.
Allele dropout due to a SNP within a priming site is a
potential risk with any PCR based assay. The use of the
probe and primers containing inosine in the current
assay addressed this concern for the most common high
frequency SNPs associated with the HBB gene. However,
with 868 known pathological mutations of the HBB
gene, as well as a number of non-pathological ones, it is
inevitable that there are SNPs associated with most
priming sites. The risk of misinterpretation due to allele
dropout is significantly mitigated by the overlapping
nature of the HRM amplicons and by the use of two
GRACE-PCR reactions. Furthermore, the fact that no
problems due to allele dropout were encountered in the
410 samples evaluated in the study indicated that the
risk is indeed small. Nevertheless, it is recommended
that the possibility of allele dropout be considered when
results of the assay do not correlate with other labora-
tory findings or the clinical picture.
The general purpose of gene scanning is to identify
amplicons carrying variant sequences. The HRM-PCR
profiles of the amplicons not only indicated the presence
of a variation in the sequence, but also often allowed the
identification of the exact nucleotide change. In the 68
blindly analysed samples all variant sequences were
correctly detected. Furthermore, in 84 % of these cases
the melting curves were sufficiently distinctive for the
correct genotype to be assigned prior to sequencing
(Table 3; columns Sample set 2 versus Sample set 1). We
believe, as more experience is gained with this assay,
provisional direct genotyping of almost all samples
should be possible. The observed genotyping ability of
HRM-PCR for the HBB gene contrasts favourably with
denaturing HPLC (DHPLC) assays, as DHPLC may re-
quire either a two-step assay [46], or may require to be
repeated after spiking with control DNA from a known
variant [47].
When a mutation occurred in overlapping amplicon re-
gions (Fig. 1 and Table 1) it was detected in both amplicons
(Table 3). This provided additional information assisting in
the assignment of the correct genotype. For example, a
sample found to be positive with both primer sets H4 and
H5 was likely to be either HBB:c.126_129delCTTT,
HBB:c.135delC or HBB:c.140G >A, since they were the
only mutations identified in the current study that oc-
curred in this region of overlap.
Interestingly, SNPs in linkage disequilibrium with patho-
logical mutations also provide additional information which
assists in assigning the correct genotype. For example, an
association between Hb Monroe (HBB:c.92G >C) and the
SNP (HBB:c.-92C >G) in the HBB gene promoter has been
reported [48]. In the current study three cases of Hb
Table 2 Primers used to generate amplicons for sequencing and Gap-PCR


























The primers used to generate amplicons for sequencing the HBB gene are shown along with the appropriate PCR reaction conditions. The sequencing primers
were synthesized with M13 tails. Primers used for the detection of the Filipino β-thalassaemia deletion by Gap-PCR are also shown (without M13 tails)
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Table 3 Mutations of the HBB gene detected by the HRM-PCR assay and GRACE-PCR









(n = 410) (n = 342) (n = 68)
1. HBB:c.-151C > T -101 C > T 2 1 1a H1 β+ thalassaemia trait
2. HBB:c.-138C > A -88 C > A 5 3 2a H1 β+ thalassaemia trait
3. HBB:c.-138C > A; HBB:c.92 + 5G > C -88 C > A; IVS1-5 G > C 1 1 0 H1 + H3 β thalassaemia major
4. HBB:c.-121C > T -71C > T 1 1 0 H1 β+ thalassaemia trait
5. HBB:c.17_18delCTb Codon 5-CT 13 12 1 H2 βo thalassaemia trait
6. HBB:c.17_18delCT; HBB:c.92 + 5G > Cb Codon 5 -CT; IVS1-5 G > C 1 1 0 H2 + H3 β thalassaemia major
7. HBB:c.19G > A Hb C 7 5 2 H2 Hb C trait
8. HBB:c.19G > A; HBB:c.20A > T Hb C; Hb S 1 0 1a H2 Hb SC disease
9. HBB:c.20A > T heterozygoteb Hb S 24 21 3 H2 Hb S trait
10. HBB:c.20A > T homozygoteb Hb S 18 18 0 H2 Hb S disease
11. HBB:c.20A > T;HBB:c.92 + 5G > Cb Hb S; IVS1-5 G > C 3 3 0 H2 + H3 Hb S disease
12. HBB:c.20A > T; HBB:c.83-22_95delb Hb S; 25 bp deletion 2 2 0 H2 + H4 Hb S disease
13. HBB:c.20A > T; HBB:c.176C > A Hb S; Hb Sheffield 1 1 0 H2 + H5 Hb S + Hb Sheffield
14. HBB:c.20A > T; HBB:c.364G > C Hb S; Hb D 2 2 0 H2 + H7 Hb SD disease
15. HBB:c.25_26delAAb Codon 8 -AA 3 3 0 H2 βo thalassaemia trait
16. HBB:c.27_28insGb Codon 8/9 + G 5 4 1a H2 βo thalassaemia trait
17. HBB:c.33C > A; HBB:c.51delC Codon 10 C > A; Codon 16 -C 1 1 0 H2 + H3 β thalassaemia major
18. HBB:c.47G > Ab Codon 15 G > A 6 4 2a H2 βo thalassaemia trait
19. HBB:c.67G > T Codon 22 G > T 2 2 0 H3 βo thalassaemia trait
20. HBB:c.79G > A Hb E 7 5 2 H3 Hb E trait
21. HBB:c.79G > A; HBB:c.126_129delCTTT Hb E; Codon 41/42 -CTTT 2 1 1 H3 + H4 + H5 Hb E/βo thalassaemia
22. HBB:c.92G > C; HBB:c.-92C > G Hb Monroe 3 1 2a H1 + H3 βo thalassaemia trait
23. HBB:c.92 + 1G > Ab IVS1-1 G > A 16 12 4 H3 βo thalassaemia trait
24. HBB:c.92 + 5G > Cb IVS1-5 G > C 96 82 14 H3 β+ thalassaemia trait
25. HBB:c.92 + 6 T > Cb IVS1-6 T > C 7 6 1a H3 β+ thalassaemia trait
26. HBB:c.92 + 6 T > C; HBB:c.93-21_96delb IVS1-6 T > C; 25 bp deletion 1 1 0 H3 + H4 β thalassaemia major
27. HBB:c.93-21_96delb 25 bp deletion 35 27 8 H4 βo thalassaemia trait
28. HBB:c.93-21G > Ab IVS1-110 G > A 18 11 7 H4 β+ thalassaemia trait
29. HBB:c.112delTb Codon 36/37 -T 1 1 0 H4 βo thalassaemia trait
30. HBB:c.114G > A Codon 37 G > A 1 1 0 H4 βo thalassaemia trait
31. HBB:c.118C > Tb Codon 39 C > T 16 13 3 H4 βo thalassaemia trait
32. HBB:c.126_129delCTTTb Codon 41/42 -CTTT 2 2 0 H4 + H5 βo thalassaemia trait
33. HBB:c.135delCb Codon 44 -C 14 10 4 H4 + H5 βo thalassaemia trait
34. HBB:c.140G > A Hb K-Ibadan 1 1 0 H4 + H5 Hb K-Ibadan
35. HBB:c.157G > C Hb Summer Hill 1 1 0 H5 Hb Summer Hill
36. HBB:c.251delG Codon 82/83 -G 6 6 0 H6 βo thalassaemia trait
37. HBB:c.315 + 1G > Ab IVS2-1 G > A 14 10 4 H6 βo thalassaemia trait
38. HBB:c.316-106G > Cb IVS2-745 G > C 1 1 0 H8 β+ thalassaemia trait
39. HBB:c.316-3C > A IVS2-848 C > A 1 1 0 H8 + H9 β+ thalassaemia trait
40. HBB:c.321_322insG Codon 105/106 + G 1 1 0 H8 + H9 βo thalassaemia trait
41. HBB:c.364G > C Hb D Los Angeles 14 14 0 H9 Hb D trait
42. HBB:c.316-149_*342delinsAAGTAGA 619 bp deletion (hetero) 1 1 0 G2 βo thalassaemia trait
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Monroe in association with HBB:c.-92C >G were found
(Table 3; Genotype 22). The Hb Monroe mutation and the
SNP resulted in distinctive melting curves in amplicons
obtained with primer sets H3 and H1, respectively.
No mutations were found in the region of the HBB
gene scanned by primer sets H7, H10 and H11, indicat-
ing that mutations in this part of the gene are compara-
tively rare in the population studied (Table 3). It is
interesting to note that even in the highly heterogeneous
population of the UAE, 91 % of positive cases could be
detected using just 5 of the 13 primer sets. This suggests
that a stepwise approach could be used starting with
high mutation frequency amplicons, thus reducing the
number of PCR reactions required to obtain results.
The combination of the HRM-PCR and GRACE-PCR
assays theoretically cover 97 % of the mutations listed
in the HbVar database [3]. This compares favourably
with previously described assays that range from 35 to
90 % theoretical coverage [29, 30]. An example of a
mutation that would not be detected by the current as-
says is HBB:c.203_204delTG [35] due to lack of overlap
between primer sets H5 and H6. Similarly, HBB:c.316-
146 T > G and HBB:c.316-125A > G [3] would not be
detected due to lack of overlap between primer sets H7
and H8.
Only negative (wild type) controls were included in
the current study, since all samples screened were also
sequenced. However, when using the assays for clinical
testing, the inclusion of appropriate positive and nega-
tive controls with each run is highly recommended. Such
controls could be genomic DNA from confirmed cases
or plasmids [29].
In our laboratory, the costs for scanning the HBB gene
with the combined HRM-PCR/GRACE-PCR assay were
approximately one eighth the cost of sequencing. Given
that in at least 84 % of cases HRM-PCR allowed the
assignment of a provisional genotype, this represents an
opportunity for significant cost savings. Should sequen-
cing be required to evaluate an unexpected melt curve,
this can be performed by directly sequencing the positive
HRM amplicon [20], which is still cheaper and faster
than sequencing the entire HBB gene. In addition, the
HRM-PCR / GRACE-PCR approach allows the detection
of large deletions which are not readily detected by
sequencing. In the current study, the samples were
manually pipetted and processed in batches of 72 PCR
reactions. Since both HRM-PCR and GRACE-PCR lend
themselves to automation, robotic reaction setup is pos-
sible, and if a micro-titre plate based PCR system was
used, up to 384 reactions could be run simultaneously
on a single plate. Although we used different annealing
temperatures, all the primers used for HRM-PCR will
perform adequately at 55 °C, which would simplify batch
processing if micro-titre plates were adopted.
In conclusion, the current study has resulted in the
development of a robust assay for the detection of
pathological HBB gene mutations. The approaches used
for handling the high frequency SNPs mean that the
assay is universally applicable, rather than being popula-
tion specific. The inclusion of GRACE-PCR targeting
both the gene promoter and third exon means that the
assay has the ability to detect a wide range of large dele-
tions of the HBB gene. The assay has sensitivity and speci-
ficity comparable to sequencing and was able to detect all
mutations in the samples tested. Furthermore, this assay
can be run at a fraction of the cost of a full sequencing
approach as 84 % of positive samples could be provision-
ally genotyped. The assay has provided useful data on the
spectrum of HBB gene mutations in the highly heteroge-
neous population of the United Arab Emirates. In future it
should be able to serve as a screening test for suspected β-
thalassaemia carriers and variant haemoglobins.
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Table 3 Mutations of the HBB gene detected by the HRM-PCR assay and GRACE-PCR (Continued)
43. HBB:c.316-149_*342delinsAAGTAGA 619 bp deletion (homo) 1 1 0 G2 β thalassaemia major
44. NG_000007.3:g.66258_184734del118477 Filipino deletion 3 2 1 G1 + G2 βo thalassaemia trait
False positive by HRM - 1 0 1 Not applicable
No mutation detected 49 44 4 - Not applicable
Samples were analysed by HRM-PCR either after (Sample set 1; n = 342) or prior to (Sample set 2; n = 68) sequencing of the HBB gene. HRM-PCR correctly identified
all samples with pathological sequence variations (n = 355). Furthermore, it was possible to correctly assign a genotype based on the HRM-PCR data (Sample set
2) for all but 10 samples (indicated by aa). GRACE-PCR correctly identified two known cases with 619 bp deletions and also identified a further three cases with
deletions of both the promoter and third exon. Gap-PCR identified the 116 kb deletion for these three cases. The commercial β-Globin StripAssay used in our
laboratory for the detection of mutations of the HBB gene would be able to resolve 23 (indicated by ab) of the 44 abnormal genotypes detected
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